Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
出版年份 2019 全文链接
标题
Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 69, Issue Supplement_7, Pages S519-S520
出版商
Oxford University Press (OUP)
发表日期
2019-10-17
DOI
10.1093/cid/ciz823
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
- (2019) Patrice Nordmann et al. CLINICAL INFECTIOUS DISEASES
- The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics
- (2019) Malcom G P Page CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
- (2019) Roger Echols et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
- (2019) Takayuki Katsube et al. CLINICAL INFECTIOUS DISEASES
- Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections
- (2019) Yohei Doi CLINICAL INFECTIOUS DISEASES
- Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
- (2018) Toshiaki Aoki et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward ‘molecularly targeted’ therapy
- (2018) Nadim G. El Chakhtoura et al. Expert Review of Anti-Infective Therapy
- Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
- (2018) Evelina Tacconelli et al. LANCET INFECTIOUS DISEASES
- Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis
- (2018) Amber Martin et al. Open Forum Infectious Diseases
- Carbapenem-resistant Enterobacteriaceae in the community: a scoping review
- (2017) Ana M. Kelly et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa
- (2017) Bin Cai et al. Open Forum Infectious Diseases
- Carbapenem-resistant Enterobacteriaceae colonization (CRE) and subsequent risk of infection and 90-day mortality in critically ill patients, an observational study
- (2017) Thomas Howe McConville et al. PLoS One
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
- (2015) Amabel Lapuebla et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America
- (2013) H. W. Boucher et al. CLINICAL INFECTIOUS DISEASES
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started